Page 45 - Read Online
P. 45
Page 330 Genvigir et al. J Transl Genet Genom 2020;4:320-55 I http://dx.doi.org/10.20517/jtgg.2020.37
Ref. [50] [22] [49] [38] [41] [53] [48] [36] [54] [43]
Clinical outcomes No association of UGT1A9 c.-275T>A variant with AR No association of UGT1A9 c.-275T>A and c.98T>C variants with neutrophil UGT1A9 rs6744284CC genotype was associated with higher gastrointestinal symptom rating scale (GSRS) score for constipation at week 1 No association of UGT2B7c.-840G>A variant with diarrhea or leukopenia No association of UGT2B7 c.-900A>G variant with adverse events (diarrhea and leukopenia)
-- counts - - - -
Pharmacokinetics No association of UGT1A9 -118delT variant with MPA pharmacokinetics - No association of UGT1A9 c.-275T>A and c.98T>C variants with MPA exposure (AUC) No association of UGT1A9 c.-440C>T, c.- 331T>C and I399 T>C variants with MPA C/D (days 3-8) - UGT2B7 c.-842AA (802CC) genotype was associated with higher AcMPAG AUC 0-9 at Month 1 and 3, on sirolimus treatment (n = 40) UGT2B7 802TT genotype individuals s
Immunosuppressive regimen MMF Cyclosporine Tacrolimus Corticosteroids MMF Cyclosporine Tacrolimus Sirolimus Corticosteroids MMF Tacrolimus Corticosteroid-free One-year follow-up MMF Cyclosporine Tacrolimus Corticosteroids 40-day follow-up MMF EC-MPS Cyclosporine Tacrolimus Corticosteroids Six-month follow-up MMF Cyclosporine Tacrolimus Sirolimus Corticosteroids Three- month follow-up MMF Cyclosporine Corticosteroid-free A
Population 118 adult patients (China) 145 adult patients (Brazil) 21 adult patients (Canada) 408 adult patients (China) 109 adult patients (USA) 92 adult patients (France) 40 adult patients (Italy) 72 adult patients (Japan) 332 adult patients 38 pediatric patients (USA)
Study design Retrospective Retrospective (Case- control) Prospective Retrospective Prospective Prospective, multicenter Mixed Prospective Prospective (FDCC Study) Retrospective (Case- control)
Allele frequency c.-275A: 14% c.-440T: 3% c.-331C: 3% c.I399C: 47% rs6744284T: 32% c.-842G: 55% UGT2B7*2(T): 33% c.-840G: 50% c.-900G:45%
- - c.98C: 0% 802T: 55% 802T: 41%
Variant (802C>T, UGT2B7*2)
rs6744284 rs7438135 (c.-840G>A, c.-842G>A or c.- 900G>A) rs7662029 (c.-327G>A) rs73823859 (-79G>A) rs12233719 (c.211G>T) rs7439366 rs62298861 (IVS1+985A>G)
Gene UGT2B7